drugset
drugset / Trial / NCT05910827

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

NCT05910827 ↗

Phase 1/2 Recruiting 398 enrolled Hummingbird Bioscience Merck KGaA, Darmstadt, Germany · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers

Timeline

Start
2024-02-05
Primary completion
2027-12-01
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab Monoclonal antibody 250 mg/m2 Intravenous
Subject Docetaxel Small molecule 60 unknown Intravenous
Subject Docetaxel Small molecule 75 mg/m2 Intravenous
Subject NEZUTATUG Monoclonal antibody — Intravenous

Indications

cervical squamous cell carcinoma esophageal squamous cell carcinoma head and neck squamous cell carcinoma nasopharyngeal carcinoma non-small cell squamous lung carcinoma skin squamous cell carcinoma